Cholera vaccine live attenuated - Celldex Therapeutics

Drug Profile

Cholera vaccine live attenuated - Celldex Therapeutics

Alternative Names: CholeraGarde; Live attenuated oral cholera vaccine - Celldex Therapeutics; Peru-15

Latest Information Update: 02 May 2014

Price : $50

At a glance

  • Originator Celldex Therapeutics Inc
  • Developer International Vaccine Institute; Vaccine Technologies
  • Class Attenuated vaccines; Cholera vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cholera

Most Recent Events

  • 02 May 2014 CholeraGarde™ is still in clinical development for Cholera prevention
  • 01 Jul 2012 The International Vaccine Institute terminates a phase II trial in Cholera (vaccine given simultaneously with measles vaccine in healthy infants) in India and Bangladesh (NCT00624975)
  • 30 Jun 2011 The International Vaccine Institute completes a phase II trial in Cholera (in HIV-seropositive adults) in Thailand (NCT00741637)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top